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To investigate the mechanism by which peroxiredoxin III (PRDX3) is altered in human prostate can-
cer (PCa), we used microRNA (miRNA) target prediction program and miRNA microarray to predict
and identify miR-23b as a candidate miRNA that targets PRDX3. We showed that miR-23b sup-
presses PRDX3 protein expression in human DU145 cells under normal and hypoxic conditions.
Additionally, the clinical signiﬁcance of miR-23b and PRDX3 expression in PCa patients was also
conﬁrmed. In conclusion, our data suggest that the effects of PRDX3 in PCa progression may be
caused by the regulation function of miR-23b, and consequently, miR-23b may be involved in the
response of PCa cells to hypoxia stress.
Crown Copyright  2012 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
Prostate cancer (PCa) is one of the most prevalent malignancies
in men and the second most frequent cause of male cancer-related
death [1]. It is a clinically heterogeneous-multifocal disease and
the incidence is continuously rising. Prostate carcinogenesis and
progression are multistep processes, involving both genetic insults
to epithelial cells and changes in epithelial–stromal interactions.
Although some clinical parameters, such as serum prostate speciﬁc
antigen (PSA) levels, may provide some prognostic utility in the
treatment settings, our understanding of molecular determinants
for PCa is limited.
In all eukaryotic organisms, oxidative stress affects cells
because of an increase in oxidant generation, a decrease in antiox-
idant protection, or a failure to correct oxidative damage, which of-
ten leads to many diseases [2–5]. For example, it has been
demonstrated to inﬂuence cancer progression and treatment re-
sponse in patients with solid tumors, including PCa [6]. Somed by Elsevier B.V. on behalf of Fede
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g).
to this article.anti-oxidative enzymes, such as catalase, superoxide dismutase
(SOD) and glutathione peroxidase (GPX), can scavenge reactive
oxygen species (ROS), which is produced by mitochondria during
respiration, and, consequently, protect cells against oxidative
stress [7]. Peroxiredoxins (PRDXs) form a family of peroxidases
and are proteins with an anti-oxidative function [8]. This family
contains highly conserved small proteins which share a common
reactive Cys residue in the N-terminal region, and has already re-
vealed six members in mammalian cells. These enzymes can not
only catalyze the reduction of hydrogen peroxide (H2O2) in the
presence of thioredoxin and/or glutathione as the electron donor,
but also protect cells against oxidative stress and inﬂuence cell dif-
ferentiation and proliferation, immune response and apoptosis [9].
Loss of mitochondrial function is the key characteristic of oxidative
stress damage. Among the six isoforms identiﬁed in mammalian
cells, PRDX3 is addressed to mitochondria due to the presence of
a mitochondrial targeting sequence [10]. It has been originally
cloned out of murine erythroleukemia cells and identiﬁed as a tar-
get gene induced by oncogenic c-Myc [11]. PRDX3 plays a role in
the anti-oxidant defense system and homeostasis within the mito-
chondria [12]. Antisense experiments have shown that its expres-
sion is required for neoplastic transformation by c-myc [11].
Previous studies have been demonstrated that PRDX3 was up-reg-
ulated in breast carcinoma, neuroblastoma, cervical cancer andration of European Biochemical society. All rights reserved.
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observed the consistent overexpression of PRDX3 in PCa tissues,
which was associated with age, increased PSA, tumor stage and
Gleason score. Additionally, in our previous study [18], the differ-
ential expression of PRDX3 in PCa tissues was also validated by
the method of two-dimensional ﬂuorescence difference gel elec-
trophoresis (2D-DIGE) coupled with mass-spectrum (MS). How-
ever, the mechanism by which PRDX3 is altered in PCa has not
been extensively investigated.
MicroRNAs (miRNAs) are small, evolutionary conserved, non-
coding RNAs that regulate a variety of gene expression post-trans-
criptionally by pairing with complementary nucleotide sequences
in the 30-UTR of speciﬁc target genes [19]. MiRNAs have been found
to function as regulators of diverse cellular processes, such as pro-
liferation, differentiation, cell cycle regulation, and apoptosis, as
tumor suppressors or oncogenes, depending on the genes they tar-
get. It has been found the dysregulation of numerous miRNAs in
the initiation and progression of various cancers, which allows
miRNAs to be potentially used for cancer diagnosis and as thera-
peutic targets [20]. In the present study, we used miRNA target
prediction program TargetScan5.1 and miRNA microarray to pre-
dict and identify miR-23b as a candidate miRNA that targets
PRDX3. Then, the regulation function of miR-23b to PRDX3 was
validated by transient transfection of the PCa cell line DU145 with
oligonucleotides that mimic miR-23b and the luciferase reporter
assay. Furthermore, we investigated the clinical relevance of
PRDX3 and miR-23b in PCa.
2. Materials and methods
2.1. Cell culture
Human PCa cell line DU145 was purchased from the American
Type Culture Collection (Manassas, VA, USA) and were cultured
in RPMI 1640 medium (Hyclone, USA) supplemented with 10% fe-
tal bovine serum (Gibico, USA), 2 mM L-glutamine and antibiotics.
All cell lines were maintained at 37 C in a humidiﬁed chamber
supplemented with 5% CO2.
2.2. Patients and tissue samples
The study was approved by the Research Ethics Committee of
Guangzhou First Municipal People’s Hospital Afﬁliated Guangzhou
Medical College, China. Informed consent was obtained from all of
the patients. All specimens were handled and made anonymous
according to the ethical and legal standards.
For miRNA microarray and quantitative real-time reverse trans-
criptase PCR (qRT-PCR) analysis, frozen samples of prostate pri-
mary tumor tissues and adjacent benign prostate tissues were
collected from the tissue bank at Guangzhou Medical College.Table 1
Clinical features of all patients.
Sample type and clinical features Experiment type
miRNA microarray
Prostate cancer (cases) 4
Mean age (range, years) 70.25 ± 11.62
660 1
>60 3
Serum PSA levels (ng/ml)
<4 0
P4 4
Gleason score
<8 2
P8 2
Metastasis 0
Adjacent Benign Tissue of prostate cancer (paired) 4For miRNA in situ hybridization detection and immunohisto-
chemistry analysis, frozen tissues and tissue microarray (TMA)
were got from company (Jieqing, China), including with the detail
clinical infromation. These data is from Caucasian, and African–
American race patients. Frozen tissues include 26 PCa tissues
(aging 47–86 years, mean ± SD = 59.15 ± 8.54 years, TNM staging
from I to III) and 20 paired adjecent benign prostate tissues. Tissue
microarray includes 147 PCa tissues (aging 37–83 years, mean ± -
SD = 58.17 ± 7.04 years, TNM staging from I to III) and 28 paired
adjecent benign prostate tissues. The detail information on the
clinical features of all patients in this study was shown in Table 1.
All of the tissues for RNA extraction were obtained immediately
during the operation of transurethral resection prostate and supra-
pubic prostatectomy. None of the patients recruited in this study
had chemotherapy or radiotherapy before the surgery. The patho-
logical diagnosis was performed preoperatively and conﬁrmed
postoperatively. All patients were reviewed and all specimens
were re-examined in December, 2010.
2.3. Target prediction,
An online program Target-Scan (release 5.1) was used for pre-
dicting miRNAs that might target PRDX3.
2.4. miRNA microarray and data analysis
The miRNA microarray analysis was performed according to the
previous study of Lee et al. [21]. Data are available at the Gene
Expression Omnibus (GEO) repository database [http://
www.ncbi.nlm.nih.gov/geo/, accession number GSE34932].
2.5. qRT-PCR
The qRT-PCR analysis was performed according to the similar
protocol of our previous study [22]. For miRNA detection, miRNA
was extracted from 20 pairs of prostate primary tumor tissues
and adjacent benign prostate tissues using miRNA extraction kit
(Bioteke, China). For miRNA detection, qRT-PCR was processing
as the protocol of All-in-One™ miRNA qRT-PCR Detection Kit
(GeneCopoeia, China) described. MiRNA expression in each sample
was normalized with the housekeeping gene (RNU6B and hsa-miR-
130b) expression. The speciﬁcity of ampliﬁcation was conﬁrmed
by melting curve analysis and also by running PCR products on
agarose gels (3%). Relative quantiﬁcation of target miRNA expres-
sion was evaluated using the comparative cycle threshold (CT)
method. Mean normalized gene expression ± SE was calculated
from independent experiments. For mRNA detection, the forward
primer 50-GGA GAG TTC AAA GAC CTA AGC C-30 and reverse primer
50-CCA CTG AGA CTG CGA CAA CTT-30 were used to amplify 166-bp
transcripts of PRDX3. Gene expression in each sample wasqRT-PCR In situ hybridization Immunohistochemistry
20 26 147
68.75 ± 4.99 59.15 ± 8.54 (47–86) 58.17 ± 7.04 (37–83)
2 17 99
18 9 48
3 3 24
17 23 120
10 19 118
10 7 29
1 4 19
20 20 28
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ative quantiﬁcation of target gene expression was evaluated using
the 244CT method.
2.6. EGFP-miR-23b expression vector
We got the commercial pGCMV/EGFP/Neo-Vector(GenePharma,
China) with an over-expression of miR-23b, and the same nega-
tive-vector as control. DU145 cell was transfected through Fugene
transfecting agents (Roche) with hsa-miR-23b vector, negative
control(NC) following the manufacturer’s instructions.
2.7. Western blot analysis
Proteins were extracted at 24 h post-transfection and used for
western blot analysis. Proteins (40 lg) were fractioned by SDS–
PAGE and transferred onto Hybond nitrocellulose membranes
(GE Healthcare). Filters were blocked in PBS-Tween 20/5% skim
milk and probed with anti-PRDX3 antibody or probed with anti-
b-catenin antibodies, which were visualized by SuperSignal West
PICO chemiluminescent detection system (Pierce Biotechnology).
b-Actin was used as equal protein loading control.
2.8. Luciferase reporter assay
The miR-23b-targeted gene was evaluated by using a luciferase
reporter assay in DU145 cells. The FLuci (30-UTR of PRDX3 lucifer-
ase) vector was constructed using the pGL3 luciferase reporter vec-
tor (Promega, USA) with a fragment of mRNA 30-UTR of PRDX3,
which carries a putative miR-23b complementary site
(NM_006793.2; 30-UTR: 460–529) or mutation sequence. DU145
cells were cultivated in 24-well plates and were co-transfected
using Fugene (Roche) with 100 ng of FLuci reporter construct,
10 ng miR-23b mimic or NC mimic, and 2 ng pRL-SV40 RLuci vec-
tor (Promega). After 48 h, cells were washed by PBS, then lysised
and detected by using the dual-luciferase reporter assay system
(Promega) and bioluminescence detector Victor3V (PerkinElemer,
USA) according to the manufacturer’s instructions.
2.9. miRNA in situ hybridization in frozen section
Locked nucleic acid-modiﬁed probes biotinylated at the 50 end
(Exiqon, Denmark) were used to detect the in situ hybridization
signal for miR-23b on formalin-ﬁxed, frozen section of prostate tis-
sues. In situ hybridization was performed as described in protocol
of Enhanced sensitivity of in situ hybridization detection kit I (per-
oxidase) (MK1030, Boster, China).
2.10. Immunohistochemistry
The specimens were ﬁxed in 4% paraformaldehyde PBS solution
and subsequently processed to make parafﬁn-embedded section.
The parafﬁn-embedded tissues were cut at 4 lm and then depa-
rafﬁnized with xylene and rehydrated for further H&E or peroxi-
dase (DAB) immunohistochemistry staining employing DAKO
EnVision System (Dako Diagnostics, Switzerland). Brieﬂy, following
a brief proteolytic digestion and a peroxidase blocking of tissue
slides, the slides were incubated overnight with the primary anti-
body against target protein (PRDX3 Ab., Santa Cruz, #sc-59661) at
a dilution of 1:100 at 4 C. After washing, peroxidase labeled poly-
mer and substrate-chromogen were then employed in order to
visualize the staining of the interested proteins. In each immuno-
histochemistry run, negative controls were carried out by omitting
the primary antibody.2.11. Staining score of in situ hybridization and immunohistochemistry
In situ hybridization and immunostaining result was scored by
two independent experienced pathologists, who were blinded to
the clinicopathological data and clinical outcomes of the patients.
The scores of the two pathologists were compared and any discrep-
ant scores were trained through re-examining the stainings by
both pathologists to achieve a consensus score. The number of po-
sitive-staining cells in 10 representative microscopic ﬁelds was
counted and the percentage of positive cells was calculated. Given
the homogenicity of the staining of the target gene or proteins, tu-
mor specimens were scored in a semi-quantitative manner. The
percentage scoring of chemoreactive tumor cells was as follows:
0 (0%), 1 (1–10%), 2 (11–50%) and 3 (>50%). The staining intensity
was visually scored and stratiﬁed as follows: 0 (negative), 1 (weak),
2 (moderate) and 3 (strong). A ﬁnal score was obtained for each
case by the sum of the percentage and the intensity score.2.12. MiR-23b involvement in PCa cell lines under hypoxia
After transfection with hsa-miR-23b vector and negative con-
trol vector (NC), DU145 cells were exposed to hypoxia. Hypoxic
microenvironments were generated according to the previous
study of Metallo et al. [23] by feeding incubators with a premixed
gas composed of 1%O2, 5%CO2 and 94%N2. Non-hypoxic cells were
maintained at 37 C in a 5% CO2–95% air incubator.
The DU145 cells were divided into four groups according to the
different treatment: miR-23b-hypoxia (DU145 cells were transfec-
ted with hsa-miR-23b vector and then cultured under hypoxia),
miR-23b-normal (DU145 cells were tranfected with hsa-miR-23b
vector and then cultured under normal condition), NC-hypoxia
(DU145 cells were tranfected with negative control vector and
then cultured under hypoxia), and NC-normal (DU145 cells were
tranfected with negative control vector and then cultured under
normal condition). The mRNA expression levels of PRDX3 and
miR-23b in cells of four groups were detected by QRT-PCR (Please
see details in section 2.5). The protein expression levels of PRDX3
in cells of four groups were detected by Western blot analysis
(Please see details in section 2.7).2.13. Statistical analysis
The software of SPSS version13.0 for Windows (SPSS Inc., IL,
USA) and SAS 9.1 (SAS Institute, Cary, NC) was used for statistical
analysis. Continuous variables were expressed as X  s. Statistical
analyses of miRNA microarray and qRT-PCR were conducted using
paired t test. For in situ hybridization and immunohistochemistry
assays, 2-way ANOVA with the Bonferroni posttest was conducted.
The Spearman correlation was calculated between the expression
levels of miRNA-23b and PRDX3 in PCa tissues. Differences were
considered statistically signiﬁcant when P was less than 0.05.3. Results
3.1. MiRNA-23b targets PRDX3 in PCa tissues
Our previous study [18] performed by 2D-DIGE coupled with
MS has revealed that PRDX3 is overexpressed in human PCa tissues
(Fig. 1A and B). In the present study, using miRNA target predicting
program, we hypothesized that three miRNAs miR-23a, miR-23b
and miR-383 all targeted PRDX3 (Fig. 1E), and we performed miR-
NA microarray, qRT-PCR, transient transfection of the PCa cell line
DU145 with miR-23b vector plasmid, and luciferase reporter assay
to test our hypothesis.
Fig. 1. MiR-23b targets PRDX3. (A) Three-dimensional DIGE images of the PRDX3 spot and (B) plots of PRDX3 spot intensity values for paired samples detected by our
previous study [18]; (C) MiR-23b is downregulated in human PCa tissues detected by miRNA microarray and qRT-PCR analysis; (D) MiR-23b is downregulated in human PCa
tissues detected by qRT-PCR analysis; (E) three predicted miRNAs which target PRDX3; (F and G) the PRDX3 protein in DU145 cells by western blot at 24 h post-transfection
of miR-23b vector. b-Actin was used as an internal loading control. miR-23b vector, negative control vector (NC); (H) a RNA sequence map to show the 30-UTR of PRDX3mRNA
carries a complementary site (NM_006793.2; 30-UTR: 460–529) for the seed region of miRNA-23b; (I) luciferase report assay was performed to conﬁrm the miR-23b binding
target. The luciferase activity was detected after co-transfection of FLuci vector (30-UTR-PRDX3wt FLuci vector or 30-UTR-PRDX3mut FLuci vector), miR-23b mimic or negative
mimic into DU145 cells. ⁄P < 0.01.
Table 2
MiRNA expression ratio in prostate cancer vs. adjacent benign tissues.
Systematic name Regulation Microarray qRT-PCR
Fold-change P-value Fold-change P-value
hsa-miR-23a Down 1.69 0.25 4.32 0.14
hsa-miR-23b Down 2.70 0.03* 6.45 0.01*
hsa-miR-383 Down 1.03 0.35 0.58 0.48
* P < 0.05.
2454 H.-c. He et al. / FEBS Letters 586 (2012) 2451–2458According to the results of miRNA microarray analysis, among
three candidate miRNAs, only miR-23b expression in PCa tissues
was signiﬁcantly lower than that in adjacent benign prostate tis-
sues [Average Ratio (2|44CT|) = 2.70, P = 0.03, Fig. 1C, Table 2],
which was further validated by qRT-PCR analysis [Average Ratio(2|44CT|) = 6.45, P = 0.01, Fig. 1C; Average 4CT (U6 CT-miR-
23b CT) of miR-23b in PCa = 2.81 and in Benign = 0.12,
Fig. 1D; Table 2].
To verify our predicted target of hsa-miR-23b, we transfected
DU145 cells with hsa-miR-23b vector, negative vector, and blank
Table 3
Association of miRNA-23b and PRDX3 expression with the clinicopathological features of PCa patients.
Clinical features hsa-miR-23b PRDX3
Case No. X  s P Case No. X  s P
Age (years)
<60 17 3.85 ± 0.79 0.63 90 5.23 ± 0.59 0.03*
P60 9 3.60 ± 0.91 57 5.00 ± 0.66
Serum PSA levels (ng/ml)
<4 3 3.96 ± 0.56 0.27 24 5.08 ± 0.15 0.64
P4 23 3.78 ± 0.85 120 5.15 ± 0.06
Gleason score
<8 19 4.22 ± 0.66 0.006** 118 5.20 ± 0.05 0.04*
P8 7 3.05 ± 0.73 29 4.91 ± 0.16
Clinical stage
<T2A 18 3.78 ± 0.91 0.35 79 5.05 ± 0.08 0.02*
PT2A 8 4.10 ± 0.83 63 5.28 ± 0.07
Pathological stage
T2A–T2C 19 4.17 ± 0.61 0.03* 86 5.15 ± 0.06 0.04*
T3A–T4 7 3.37 ± 0.69 61 5.12 ± 0.09
Metastasis
No 22 4.64 ± 0.52 0.004** 119 5.18 ± 0.56 0.21
Yes 4 2.70 ± 1.07 28 4.96 ± 0.86
* P < 0.05.
** P < 0.01.
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at 24 h post-transfection, overexpression of hsa-miR-23b resulted
in a signiﬁcant decrease of endogenous PRDX3 protein levels, com-
pared with cells transformed with NC or mock (Fig. 1F and G).
Furthermore, the luciferase reporter assay was performed to
conﬁrm the miR-23b-binding site on the 30-UTR region of PRDX3
mRNA. Fig. 1H showed a sequence map in which the 30-UTR of the
PRDX3 mRNA fragment carries a complementary site
(NM_006793.2; 30-UTR: 460–529 for the seed region of miRNA-
23b or mutation sequence. Luciferase activity was detected 48 h
after the co-transfection of FLuci vector (30-UTR-PRDX3wt FLuci
vector or 30-UTR-PRDX3mut FLuci vector), miR-23b mimic or NCFig. 2. MiRNA-23b expression was veriﬁed by in situ hybridization (original magniﬁca
tissues; (B) the miRNA-23b signal was weak in the PCa tissues; (C) positive control (U6mimic, and RLuci vector in DU145 cells. The luciferase activity
was decreased to 0.632 in DU145 cells cotransfected with 30-UTR-
PRDX3wt FLuci vector and miR-23b mimic compared with 30-
UTR-PRDX3mut FLuci vector and NC mimic (Fig. 1I).
Taken together, these observations suggested that MiR-23b di-
rectly targets PRDX3.
3.2. Expression of miRNA-23b and PRDX3 protein in PCa and adjacent
benign prostate tissues
We validated the miRNA-23b expression by in situ hybridiza-
tion. Fig. 2 shows the representative images of miRNA-23btion 400). (A) The miRNA-23b signal was strong in the adjacent benign prostate
); (D) blank control. Red arrows indicate the positive signals.
Fig. 3. Immunohistochemical staining for PRDX3 in PCa (original magniﬁcation 400). (A) PRDX3 weakly positive staining was found in cytoplasm of adjacent benign
prostate tissues. (B) PRDX3 strongly positive staining in PCa was found in cytoplasm of PCa tissues. (C) No staining was seen when omission of the primary antibody was
served as blank controls. (D) The immunoreactivity score of PRDX3 staining result. Red arrows indicate the positive signals.
2456 H.-c. He et al. / FEBS Letters 586 (2012) 2451–2458expression by in situ hybridization from 26 PCa and 20 adjacent
benign prostate tissues. The expression levels of miRNA-23b in
PCa tissues were lower than those in adjacent benign prostate tis-
sues signiﬁcantly (staining score: PCa = 3.63 ± 0.81 vs. Be-
nign = 4.56 ± 0.66, P < 0.001).
The expression and localization of PRDX3 in the 147 PCa and 28
adjacent benign prostate tissues were examined using immuno-
histochemical analysis. Fig. 3 shows the representative images of
PRDX3 expression by immunohistochemistry analysis. The expres-
sion levels of PRDX3 in PCa tissues were higher than that in adja-
cent benign prostate tissues (staining score: PCa = 5.23 ± 0.49 vs.
Benign = 4.63 ± 0.58, P = 0.04) signiﬁcantly. The PRDX3 expression
occurred mainly in the cytoplasm, which is similar to the results
from the previous studies [17]. The Spearman Correlation analysis
showed the signiﬁcant correlation between the expression levels
of PRDX3 protein and miRNA-23b in PCa tissues (rs = 0.58,
P = 0.03).
3.3. Association of miRNA-23b and PRDX3 expression with the
clinicopathological characteristics of PCa
The association of miRNA-23b and PRDX3 expression with the
clinicopathological features of PCa patients is shown in Table 3.Fig. 4. MiR-23b up-regulation suppresses PRDX3 expression in DU145 cells under hypo
miR-23b-hypoxia and miR-23b-normal cells. (C and D) PRDX3 protein expression of inThe reduced expression of miR-23b was frequently found in PCa
tissues with metastasis (P = 0.004), higher Gleason score
(P = 0.006) and pathological stage (P = 0.03), whereas the up-regu-
lation of PRDX3 protein was associated with older patients’ age
(P = 0.03), higher Gleason score (P = 0.04), high pathological stage
(P = 0.04) and clinical stage (P = 0.02).
3.4. Overexpression of miR-23b suppresses the response of PRDX3 to
hypoxia condition in Du145 cell line
The mRNA and protein expression of PRDX3 in NC-hypoxia cells
were both signiﬁcantly higher than those in NC-normal cells (NC-
hypoxia vs. NC-normal: both P < 0.001, Fig. 4). Obviousely, the
overexpression of miR-23b in hsa-miR-23b vector transfected
DU145 cells could signiﬁcantly suppress the up-regulation of
PRDX3 mRNA and protein under hypoxia and nomoxia (miR-23b-
nomal vs. NC-normal, and miR-23b-hypoxia vs. NC-hypoxia: both
P < 0.001, Fig. 4). However, in hsa-miR-23b vector transfected
DU145 cells, PRDX3 mRNA and protein expression levels had no
statistically signiﬁcant differences between normal and hypoxic
conditions (miR-23b-hypoxia vs. miR-23b-normal: both P > 0.05,
Fig. 4). These results suggested the overexpression of miR-23b
could inhibit the response of PRDX3 to hypoxic condition.xia. (A and B) PRDX3 mRNA and miR-23b expression of in NC- hypoxia, NC-normal,
NC- hypoxia, NC-normal, miR-23b-hypoxia and miR-23b-normal cells. ⁄P < 0.001.
Fig. 5. Illustration of pathways involved by c-myc, PRDX3 and miRNA-23b.
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PCa is the most frequently occurring cancer in men of the Uni-
ted States and advanced metastatic PCa is currently incurable. It is
the great challenge of current basic and clinical research to identify
novel molecular targets that could improve the therapeutic strate-
gies to combat this lethal cancer. The main ﬁndings of the present
study are as following three points. Firstly, we used miRNA target
prediction program and miRNAmicroarray analysis to ﬁnd an miR-
NA–miR-23b that potentially regulated PRDX3, and selected PCa
cell line-DU145 for veriﬁcation using transfected miRNA overex-
pression vector. In the transfected cells, PRDX3 was downregulated
at protein level by the proposed target miRNA, miR-23b, which
was further conﬁrmed by the luciferase reporter assay, suggesting
that PRDX3 is a target of miR-23b in PCa cells. Secondly, the
expression levels of miR-23b and PRDX3 in PCa tissues was related
to the severity of the tumor malignancy. Finally, miR-23b up-reg-
ulation in PCa cell lines could suppress the response of PRDX3
expression to hypoxic condition.
PRDX proteins are important regulators of cellular anti-oxidant
defense, and are demonstrated to be involved in malignant trans-
formation and therapy resistance. The multifunctional PRDXs have
been implicated in prostate carcinogenesis. Previous study has re-
ported that PCa cell lines coexpressed PRDXs at the protein levels
[22]. Stable transfection with antisense allowed partial, selective
suppression of PRDX 1, 2, 3, or 4. PCa cells were rendered more
sensitive to hydrogen peroxide or an organic hydroperoxide when
PRDX 1, 2, or 3 but not 4 was partially suppressed [24]. The ele-
vated expression of PRDX1 enhances androgen receptor (AR) trans-
activation, which plays an important role in PCa, by hypoxia/
reoxygenation and sensitizes a ligand-stimulated AR, consequently
providing a survival advantage to PCa cells subjected to an adverse
microenvironment [25]. PRDX1 has been considered as a therapeu-
tic target in blocking the transition of PCa from an androgen-
dependent to an androgen-refractory phenotype [26]. Additionally,
the differential expressions of PRDX3 and PRDX4 have been found
in PCa [16]. Similarly to these results, our previous study also dem-
onstrated the PRDX3 protein is up-regulated in PCa comparing
with adjacent benign prostate tissues [18]. Further investigations
of PRDX3 expression mechanisms in PCa are needed. Previous
studies suggested that PRDX3 may be regulated by c-myc, which
is implicated in the control of a variety of cellular processes,
including cell growth, cell-cycle progression, and apoptosis
[27,28]. Wonsey et al. [27] indicated that the deregulated overex-
pression of c-myc, which mimics conditions found in cancer cells,
could induce PRDX3 and facilitate accelerated cellular growth of
cancer cells. The current study demonstrated that PRDX3 is a target
of miR-23b in PCa cells. MiR-23b is involved in tumor invasion and
metastasis [29]. It has been demonstrated to be downregulated in
human colon cancer tissues [30]. MiR-23b directly regulates a co-
hort of pro-metastatic genes or oncogenes, including FZD7,
MAP3K1, PAK2, TGF-b, RRAS2 or uPA, which respectively partici-
pate in the ERK, JNK, NF-jB, PI3K, TGF-b and Wnt pathways
[31,32].
On the other hand, the Warburg effect refers to the high rate of
glycolysis and lactate fermentation in the cytosol exhibited by
most cancer cells, relative to the comparatively low rate of glycol-
ysis and oxidation of pyruvate in mitochondria exhibited by most
normal cells [33]. On the basis of the Warburg effect, cancer cells
also depend on continued mitochondrial function for metabolism,
speciﬁcally glutaminolysis that catabolizes glutamine to generate
ATP and lactate [34]. Recent studies have reported that the c-
myc could transcriptionally represses APO (C9orf3), resulting in
less expression of miR-23b which is encompassed by C9orf3 [34].
Therefore, myc represses miR-23b, which seems to be directlyregulated by Myc. The data in the current study for the ﬁrst time
to show that miR-23b could directly regulated PRDX3 expression
under normal and hypoxic conditions. We propose that c-
myc? PRDX3 and c-myc?miR-23b? PRDX3 may both have
critical roles in prostate carcinogenesis (Fig. 5).
In conclusion, our data offer the convince evidence that the
abnormal expression of miR-23b and PRDX3 may be associated
with the aggressive progression of PCa patients. Notably, we found
that the expression level of miR-23b in PCa tissues was signiﬁ-
cantly correlated with that of PRDX3, which suggested that the ef-
fects of PRDX3 in PCa progression may be caused by the regulation
function of miR-23b, and consequently, miR-23b may be involved
in the response of PCa cells to hypoxia stress. Thus, gene therapy
using miRNA mimics may be useful as a PCa therapy.
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